Kansai Startup Coalition Partners with Alloy Therapeutics to Boost Biotech Startups in Japan

Kansai and Alloy are in a Collaboration to Leverage Growth in Japan

Announcement

Kansai Startup Academia Coalition, represented by Kyoto University, fostered to expansion university university-affiliated life science startups throughout Japan, and Alloy Therapeutics co, Ltd. has signed a memorandum of understanding (MOU). This collaboration will leverage research and development (R&D) activities by enabling connections with academic innovations with the worldwide biopharmaceutical industry and providing complex support. The history of KSAC is a coalition of above 90 academic institutions in western Japan, built under the leadership of Kyoto University and with the help of Japan’s Ministry of Education, Sports, Culture, and Science and Technology (MEXT). The KSAC’s motive is to bring industry and academia together by initiating GAP funds for research, also by supporting digital workshop networks, providing entrepreneurship education, and highlighting early-stage technologies via exhibitions and events at the international and domestic levels.

Plans

Alloy Therapeutics Inc. is a Boston-based biotechnology ecosystem company with platform technologies and unique services, as well as a venture studio, 82VS has elevated the discovery of drugs. With the MOU KSAC and alloy Japan will discuss to merge academic seeds from Japan to biopharma’s worldwide markets. It will also introduce important insights from the vast community to stimulate Japan’s startup ecosystem. This strategic collaboration will focus on advancing complex capabilities through Japan’s entrepreneurial and academic community to initiate the development of highly competitive life science startups.

The first step to this interaction will be to secure Japan’s support for the KSAC’s GAP fund program. It will enable funding for specific academic projects under the KSAC network. This 3-year term of the MOU seeks extension to additional KSAC initiatives that aim at forming a worldwide integration and advancing the biotech community.

Views and Statements

Director general of the office of institutional advancement and communications at Kyoto University, representing KSAC, Koji Murota, said, “Alloy’s ability and broad network strengthen our mission of encouraging academic startups to perform internationally. Alloy Japan provides a highly distinct contribution to our activities with venture capital firms and global incubators. By engaging with ecosystem builders such as Alloy Japan, we can enable our entrepreneurs and researchers with additional scientific resources, opportunities, and biopharma insights to uplift their innovations across and beyond Japan.”

CEO of Alloy Japan, Victor Stone (Yoshihide Ishii), said, “By working with KSAC and its networking universities, we focus on strengthening the integration of biopharma’s ecosystem and Japanese academic excellence.”